Key Takeaways
- • US venture capital firm Proximal Ventures closed its debut fund at $27.5m, exceeding its $25m fundraising target.
- • Backers include Kleiner Perkins, SignalFire and Bertelsmann Healthcare Investments, per the publisher summary.
- • The fund targets AI-driven life sciences investments, making it a first-time vehicle for a specialist healthcare-focused venture manager.
Summary
US venture capital firm Proximal Ventures has closed its debut fund at $27.5m, according to AltAssets, beating its $25m target. The fundraise drew backing from investors including Kleiner Perkins, SignalFire and Bertelsmann Healthcare Investments.
The fund is dedicated to AI-driven life sciences investments. The close of a first-time fund above its original target is a relevant data point for allocators assessing emerging managers in the healthtech and AI-enabled biotech segments, where capital has been concentrated among established platforms.
The primary source available for this story is limited to the publisher summary and a headline, as the full article is behind a premium subscription wall. Further details on the fund's strategy, investment thesis, target sectors, and portfolio plans were not available in the source material reviewed.
The fund is dedicated to AI-driven life sciences investments. The close of a first-time fund above its original target is a relevant data point for allocators assessing emerging managers in the healthtech and AI-enabled biotech segments, where capital has been concentrated among established platforms.
The primary source available for this story is limited to the publisher summary and a headline, as the full article is behind a premium subscription wall. Further details on the fund's strategy, investment thesis, target sectors, and portfolio plans were not available in the source material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.